Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VP 025

Drug Profile

VP 025

Alternative Names: VP-025

Latest Information Update: 30 Oct 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vasogen
  • Developer Intellipharmaceutics International
  • Class Anti-inflammatories; Antidementias; Antiparkinsonians; Nootropics; Phospholipids
  • Mechanism of Action Cytokine inhibitors; Cytokine modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Alzheimer's disease; Amyotrophic lateral sclerosis; Diabetic retinopathy; Neurological disorders; Parkinson's disease

Most Recent Events

  • 22 Oct 2009 Vasogen has merged with IntelliPharmaCeutics Corp to form Intellipharmaceutics International
  • 09 Jul 2008 Suspended - Phase-I for Neurological disorders in Canada (unspecified route)
  • 09 Jul 2008 Suspended - Preclinical for Alzheimer's disease in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top